<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03064802</url>
  </required_header>
  <id_info>
    <org_study_id>SP001</org_study_id>
    <nct_id>NCT03064802</nct_id>
  </id_info>
  <brief_title>Burst Biologics Spinal Fusion Registry</brief_title>
  <official_title>Multicenter Prospective Registry to Evaluate Use and Outcomes of Burst Biologics Products in Spinal Fusion Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Burst Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smart-Surgical Inc. dba Burst Biologics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter patient registry was created with aim of documenting how spine and
      neurosurgeons are utilizing Burst Biologics products along with patient outcomes. These
      include radiographic measures such as fusion outcome, instrumentation integrity, and clinical
      outcomes (symptom and function improvement) based on surgeon and patient based outcome
      assessments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spinal fusion surgery remains the most common intervention despite the increasing prevalence
      of various motion preservation and alternative stabilization devices for patients who are
      unresponsive to conservative treatment and experience back and/or leg pain and decreased
      function/quality of life. Donor site morbidity and availability limit the use of autogenous
      bone and over the past two decades' surgeon interest in alternative bone grafts has steadily
      increased. Bone morphogenic proteins, synthetic bone graft substitutes, and various allograft
      products are widely available to surgeons. Limitations on the use of allografts in the past
      were mainly attributed to less than optimal donor screening and processing techniques which
      removed viable components needed to aid in the bone healing process.

      In recent years, the focus and scientific advances in various allograft processing techniques
      have allowed the retention of various viable cytokines, growth factors, and cell populations
      which result in enhanced osteogenic and osteoinductive properties. Rigorous donor bone
      screening and meticulous testing has virtually eliminated the risk of disease transmission.

      A unique proprietary cryoprotection processing technique (ProgenokineÂ®) for allograft tissue
      was developed by Smart-Surgical, Inc. and a complete line of allograft products was created
      and is now marketed by Burst Biologics (dba). In addition, rigorous standardized laboratory
      assay techniques and statistical analysis provide consistency and uniformity of the
      biologically active components of Burst allograft products.

      This prospective registry was designed as an observational study to ascertain how
      commercially available Burst Products are being used by surgeons performing spinal fusion as
      well as determining relevant patient outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Fusion Rate (%) . Number of patients fused/all patients operated (%)</measure>
    <time_frame>12 Months</time_frame>
    <description>Determined by CT Scan or Plain Radiographs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Oswestry Disability Index (ODI)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Short Form-36 V2</measure>
    <time_frame>12 Months</time_frame>
    <description>SF36V2 Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Neck Disability Index (NDI)</measure>
    <time_frame>12 Months</time_frame>
    <description>NDI Score</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <condition>Spinal Stenosis</condition>
  <condition>Spondylitis</condition>
  <condition>Spondylolisthesis</condition>
  <condition>Herniated Disk</condition>
  <arm_group>
    <arm_group_label>BioBurst Fluid, Burst Allograft</arm_group_label>
    <description>Spinal Fusion with BioBurst Fluid or Burst Allograft</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioBurst Fluid, Burst Allograft</intervention_name>
    <description>BioBurst Fluid or Burst Allograft used to augment spinal fusion</description>
    <arm_group_label>BioBurst Fluid, Burst Allograft</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients in the study will be drawn from the individual surgeons practice. Patients
        will be either candidates for spinal fusion surgery after having failed conservative
        treatment or will have had spinal fusion surgery and the surgeon determined that the use of
        a Burst Biologic product is or was clinically indicated.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged 18 years or older

          -  Patient diagnosed with a degenerative spine disorder, has failed conservative
             treatment, and has decided to undergo surgery.

          -  The surgeon has determined that a Burst Biologic product is or was clinically
             indicated.

          -  Patient capable of understanding the content of the Informed Consent Form

          -  Patient willing and able to participate in the registry protocol including follow-up
             visits and clinical evaluations.

          -  Patient who has agreed to participate in the registry by providing consent according
             to the applicable local law and the declaration of Helsinki.

        Exclusion Criteria:

        The following are relative contraindications for the use of Burst Products, however the
        investigator surgeon is solely responsible for the determination of patient eligibility for
        surgery:

          -  Severe vascular or neurological disease

          -  Uncontrolled diabetes

          -  Severe degenerative disease (other than degenerative disc disease)

          -  Hypercalcemia, abnormal calcium metabolism

          -  Existing acute or chronic infections, especially at the site of the operation

          -  Inflammatory bone disease such as osteomyelitis

          -  Malignant tumors

          -  Patients who are or plan to become pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven M Czop, R.Ph.</last_name>
    <role>Study Director</role>
    <affiliation>Medical Affairs Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven M Czop, R.Ph.</last_name>
    <phone>888-322-1191</phone>
    <email>Sczop@smart-surgical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orlando Neurosurgery</name>
      <address>
        <city>Winter Garden</city>
        <state>Florida</state>
        <zip>34787</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ravi H Gandhi, MD</last_name>
      <phone>407-975-0200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polaris Spine and Neurosurgery Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas J Morrison, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carrollton Orthopaedic Clinic</name>
      <address>
        <city>Carrollton</city>
        <state>Georgia</state>
        <zip>30117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brad G Prybis, MD</last_name>
      <phone>770-834-0873</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Spine Care</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul M Brisson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma Spine and Brain Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank J. Tomecek, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2017</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Smart-Surgical Inc. dba Burst Biologics</investigator_affiliation>
    <investigator_full_name>Burst Biologics</investigator_full_name>
    <investigator_title>Medical Affairs Officer</investigator_title>
  </responsible_party>
  <keyword>BioBurst</keyword>
  <keyword>Spinal Fusion</keyword>
  <keyword>Cellular Allograft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spinal Stenosis</mesh_term>
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
    <mesh_term>Spondylolisthesis</mesh_term>
    <mesh_term>Intervertebral Disc Displacement</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

